Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28992174.
- Also identified by DOI 10.1093/rheumatology/kex203 and PMC identifier 5850349.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (SSc-ILD). Large randomized clinical trials in SSc-ILD have provided important information regarding the feasibility, reliability and validity of outcome measures. Forced vital capacity percentage predicted should be considered as a primary outcome measure, with inclusion of appropriate radiological and patient-reported measures. We provide practical recommendations for trial design in SSc-ILD.
Medical subject headings
- Clinical Trials as Topic
- Disease Management
- Lung Diseases, Interstitial
- Scleroderma, Systemic